Solriamfetol within its marketing authorisation for treating excessive waketime sleepiness caused by narcolepsy
 
Status Proposed
Process STA 2018
ID number 1602

Provisional Schedule

Committee meeting 07 July 2020
Expected publication 16 September 2020

Project Team

Project lead Gemma Barnacle

Email enquiries

Evidence Review Group / Assessment Group Southampton Health Technology Assessment Centre (SHTAC), University of Southampton

Consultees

Companies sponsors Jazz Pharmaceuticals (solriamfetol)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Professional groups Association of British Neurologists
  British Thoracic Society
  Royal College of Physicians
  Royal Society of Medicine – Sleep medicine section

Commentators

Comparator companies Accord-UK (methylphenidate) (confidentiality agreement not signed, not participating)
  Aurobindo Pharma - Milpharm (modafinil) (confidentiality agreement not signed, not participating)
  BioProjet (pitolisant hydrochloride) (confidentiality agreement not signed, not participating)
  Flynn Pharma (dexamphetamine, methylphenidate) (confidentiality agreement not signed, not participating)
  Generics UK T/A Mylan (methylphenidate) (confidentiality agreement not signed, not participating)
  Janssen-Cilag (methylphenidate) (confidentiality agreement not signed, not participating)
  Martindale Pharma (dexamphetamine) (confidentiality agreement not signed, not participating)
  Novartis Pharmaceuticals UK (methylphenidate) (confidentiality agreement not signed, not participating)
  Sandoz (methylphenidate,) (confidentiality agreement not signed, not participating)
  Shire Pharmaceuticals Limited (methylphenidate) (confidentiality agreement not signed, not participating)
  Teva Pharma (modafinil) (confidentiality agreement not signed, not participating)
  UCB Pharma (sodium oxybate) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee

Timeline

Key events during the development of the guidance:

Date Update
28 October 2019 Please note that the company have requested additional time in order to facilitate a suitably comprehensive and robust evidence submission. NICE have agreed to this and the new deadline for submissions is expected to be early-January 2020.
08 August 2019 Invitation to participate

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance